Explain why signing and closing are separate events, and name at least three things that can change in a model's assumptions between them.

What a cumulative M&A conversation actually tests

By the time an interview reaches a full M&A conversation, the interviewer has usually stopped asking single-concept questions and started asking you to hold a deal in your head while they change one assumption at a time: "now make it a stock deal," "now assume the target fights it," "now assume rates rise 200bps." This tests integration, not recall: whether cost synergies, financing mix, purchase accounting, and process are one mental model or ten separate flashcards.

What separates a strong candidate across the whole module:

• Fluent narration of the full model, unprompted, before diving into any one piece (purchase price, financing, PPA, combined income statement, pro forma EPS, sensitivities) so the interviewer knows you can navigate the whole board before they start moving pieces on it.
• Correctly assigning certainty levels: cost synergies are more credible than revenue synergies; cash/debt financing is more certain in its EPS effect than stock (no share-count assumption risk, but real leverage and rate risk instead); sell-side final bids are judged on price and terms and financing certainty, not headline price alone.
• Running the algebra both directions: breakeven premium and breakeven synergies are the same equation solved for different variables. A candidate who can pivot between them shows real command, not memorization of one direction.
• Never treating accretion/dilution as the final word. The best candidates volunteer, without being asked, that EPS accretion is a financing-mix artifact that must be checked against NPV/value creation, leverage capacity, and strategic rationale.
• Connecting process and structure to price. A hostile approach, a contested auction, or a financing gap all change effective price and risk. A candidate who only knows the clean, negotiated-deal version of the model will be caught flat when the interviewer complicates the scenario.

The module-level signal an interviewer is listening for: can this candidate run an entire deal conversation (strategy, price, structure, accounting, process, and risk) as one continuous thread, the way they would actually have to on a live deal team?

Cross-lesson traps that show up in integrated questions

Trap 1: Solving accretion/dilution without first fixing the financing mix and purchase price. Candidates who treat the six-stage model as a checklist rather than a dependency chain often guess at accretion before they've actually built sources and uses or the PPA, and produce numbers that don't tie.

Say it out loud: "I need the purchase price and how it's financed before I can size incremental interest expense or share count, and I need the PPA before I know incremental D&A. Accretion/dilution is the last output, not the first thing I solve for."

Trap 2: Treating revenue synergies and cost synergies as equally credible in a breakeven or accretion calculation. Interviewers routinely plant an inflated revenue synergy number to see if a candidate accepts it uncritically.

Say it out loud: "I'd weight cost synergies much more heavily than revenue synergies in this math: cost synergies are more certain and faster to realize, while revenue synergies are typically haircut significantly or excluded until proven, since they depend on customer and market behavior outside the acquirer's direct control."

Trap 3: Forgetting that a stock deal's accretion depends on the acquirer's current share price, and that price can move between announcement and closing. A falling acquirer stock price between signing and close increases the effective share count for a fixed-dollar stock deal (or decreases it for a fixed-exchange-ratio deal). Candidates who don't ask which structure applies get the direction wrong.

Say it out loud: "I'd first ask whether this is a fixed-value or fixed-exchange-ratio stock deal: in a fixed-value deal, if the acquirer's stock falls before closing, more shares must be issued to deliver the same dollar value, which is worse dilution than the announcement-day model showed."

Trap 4: Ignoring that sign and close are separated by real conditionality, and pricing accretion as if it happens on day one of the announced deal. Financing costs, synergy phase-in, and even the PPA can all shift between signing and the actual closing date, especially across a multi-month regulatory review.

Say it out loud: "The accretion I show is as of the assumed closing date, not the announcement date, and if there's a long regulatory gap, I'd want to flag that financing rates, the target's standalone performance, and even the competitive landscape could all move before we actually close."

Trap 5: Treating hostile-deal defenses and process mechanics as a separate topic from the financial model, rather than an input to it. A poison pill, a staggered board, or a contested go-shop period all change the effective price, timeline, and certainty of a deal, and therefore belong in the same conversation as the accretion math, not a separate silo.

Say it out loud: "A hostile or contested process usually means a higher effective price, either from a bidding war or from defensive tactics that force a sweetened offer, so I'd expect the accretion math to look worse than a friendly negotiated deal at the same initial premium, and I'd want to rerun the model at the price the target's defenses are likely to force."

Trap 6: Presenting only the year-one accretion number and skipping the leverage and value-creation checks. A deal can look great on EPS in year one and still be a bad deal on leverage capacity or NPV grounds; presenting one number as the whole answer under-serves the question.

Say it out loud: "I'd present the year-one and run-rate accretion together with the leverage impact and a value-creation view: accretion alone tells the board how the stock might react short-term, not whether the deal is actually a good use of capital."